Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Nicholas Florko, Communications Officer, Global Trade Watch
w. (202) 454-5108

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


March 2, 2011

Misleading Communications Regarding Breast Implant-Related Cancer to Be Removed From Websites of Leading Plastic Surgery Organizations

Statement of Dr. Michael Carome, Deputy Director, Public Citizen’s Health Research Group

 The Food and Drug Administration (FDA) has taken laudable action by prompting two leading plastic surgery associations to remove misleading information regarding breast implant-related cancer from the organizations’ websites.

In a Feb. 17 letter to the FDA, Public Citizen alerted the agency that the presidents of two leading plastic surgery organizations – the American Society of Plastic Surgeons (ASPS) and the American Society for Aesthetic Plastic Surgery (ASAPS) – urged members to inaccurately downplay the significance of recent evidence about the risks of breast implant-related cancer when speaking to female patients during a recent members-only webinar posted on the ASPS and ASAPS websites. Such communications represented a deplorable attempt to trivialize the significance of the findings of increased numbers of cases of a rare form of cancer, called anaplastic large cell lymphoma (ALCL), in women with breast implants. Public Citizen called on the FDA to stop this deliberately misleading messaging campaign, the goal of which apparently was to keep women in the dark about the dangers of breast implants so they will continue to ask for them.

In a response letter written Feb. 28 and received today by Public Citizen, Dr. Jeffrey Shuren, the director of the FDA’s Center for Devices and Radiological Health, informed Public Citizen that after the FDA reviewed the ASPS/ASAPS webinar and spoke with representatives of both organizations, ASPS and ASAPS now plan to remove the misleading webinar from their websites.

In his letter, Dr. Shuren noted that while ASPS and ASAPS are independent organizations that FDA does not regulate, FDA is committed to assuring that health care providers and patients receive accurate information about the possible association between breast implants and the development of ALCL. Removal of the webinar from the ASPS and ASAPS websites is an important first step in undoing the misleading and inaccurate “educational” campaign initiated by these organizations.

Among the misleading claims made during the ASPS/ASAPS webinar was that the type of cancer seen in breast implant patients had a “benign course” and that “surgery [to treat the cancer] was curative.” However, as Dr. Shuren stated in his letter, “the optimal treatment regimen [for breast implant-associated ALCL] has not been established and … additional data collection is needed to fully understand … [its] risk factors, optimal treatment plan, and prognosis.”

The FDA plans to collaborate with ASPS and other experts in the clinical and scientific communities to develop a registry to gather additional information to better characterize ALCL in women with breast implants.

As the FDA moves forward with these plans, it is essential that the agency closely monitors the control of the registry to ensure that the integrity of the data being collected is not corrupted by those with significant conflicts of interest.


Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.